PPCB net incomeQ4 2026-$4.57M
PPCB net income was -$4.57M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$4.07M a year earlier. For the full fiscal 2026 it was -$18.86M, compared with -$58.92M in fiscal 2025.
Propanc Biopharma Inc. (PPCB) financials
For fiscal 2026 (ended Jun 30, 2026), Propanc Biopharma Inc. reported -$18.86M of net income.
- Net income, FY2026
- -$18.86M
- Free cash flow, FY2026
- -$5.69M
- EPS, diluted, FY2026
- -$17.62
- Cash
- $832.0K
- Market cap
- $1.8M
FY2017FY2026
FY2019FY2026
PPCB revenue and earnings growth
PPCB EPSFY2026-$17.62
PPCB diluted EPS was -$17.62 for fiscal 2026 (ended Jun 30, 2026).
PPCB free cash flowQ4 2026-$1.60M
PPCB free cash flow was -$1.60M in fiscal Q4 2026 (ended Jun 30, 2026). For the full fiscal 2026 it was -$5.69M.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | - | - | - | - | - | - | - | $28.1K | $30.5K | $29.0K |
| Research and development | $625.5K | $223.7K | $248.1K | $247.9K | $256.1K | $231.0K | $180.0K | $260.3K | $1.83M | $971.8K |
| Selling, general and admin | $670.6K | $109.0K | $1.25M | $1.50M | $1.71M | $1.55M | $3.28M | $2.33M | $2.10M | $4.74M |
| Operating income | -$18.19M | -$57.28M | -$1.54M | -$1.78M | -$1.99M | -$1.81M | -$3.49M | -$2.61M | -$3.96M | -$5.74M |
| Interest expense | $430.5K | $563.8K | $665.8K | $532.8K | $568.8K | $449.5K | $1.75M | $1.31M | $2.79M | $3.20M |
| Pre-tax income | -$18.86M | -$58.92M | -$1.95M | -$2.79M | -$2.71M | -$2.14M | -$4.88M | -$5.76M | -$7.04M | - |
| Income tax | - | - | -$129.1K | -$129.8K | -$55.0K | -$113.4K | -$134.7K | -$115.4K | -$179.3K | -$305.7K |
| Net income | -$18.86M | -$58.92M | -$1.82M | -$2.66M | -$2.66M | -$2.03M | -$4.74M | -$5.76M | -$7.04M | -$7.87M |
| EPS, basic | -$17.62 | -$371.22 | -$35513.25 | -$45.00 | -$1230.75 | -$20.00 | -$4811.25 | -$274.25 | -$4468.75 | -$56.00 |
| EPS, diluted | -$17.62 | -$371.22 | -$35513.25 | -$45.00 | -$1230.75 | -$20.00 | -$4811.25 | -$274.25 | -$4468.75 | -$56.00 |
| Diluted shares | 1.1M | 158,727 | 56.68 | 69,552.08 | 2,728.76 | 121,304.48 | 985.36 | 20,997.56 | 1,575.24 | 140,341.28 |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $832.0K | $12.1K | $21.1K | $10.0K | $4.1K | $2.3K | $67.0K | $2.4K | $19.9K | $69.0K |
| Current assets | $8.54M | $8.35M | $25.4K | $19.0K | $15.0K | $6.6K | $69.0K | $91.1K | $60.9K | $82.0K |
| Total assets | $12.78M | $19.63M | $72.4K | $60.3K | $81.7K | $13.1K | $98.5K | $101.7K | $71.4K | $95.1K |
| Current liabilities | $3.35M | $5.58M | $3.79M | $3.16M | $3.06M | $3.08M | $3.74M | $4.40M | $6.82M | $5.54M |
| Total debt | - | $537.9K | $399.3K | $390.5K | $926.4K | $624.6K | $1.56M | $1.66M | $4.70M | $3.48M |
| Total liabilities | $3.38M | $5.73M | $3.85M | $3.18M | $3.11M | $3.08M | $3.74M | $4.40M | - | - |
| Shareholders' equity | $9.40M | $13.91M | -$3.78M | -$3.12M | -$3.02M | -$3.07M | -$3.64M | -$4.30M | -$6.75M | -$5.44M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.68M | -$405.2K | -$935.1K | -$1.11M | -$1.44M | -$1.15M | -$1.85M | -$2.06M | -$2.18M | -$2.05M |
| Capital expenditures | $4.9K | - | - | - | - | - | - | $2.9K | - | - |
| Free cash flow | -$5.69M | - | - | - | - | - | - | -$2.06M | - | - |
| Investing cash flow | -$4.9K | - | - | - | - | - | - | -$2.9K | - | - |
| Financing cash flow | $6.46M | $490.8K | $941.9K | $1.11M | $1.49M | $1.06M | $1.89M | $2.12M | $2.40M | $2.10M |
| Stock-based compensation | $8.50M | $4.62M | - | $2.4K | $72.5K | $82.9K | $300.4K | - | $516.1K | $1.69M |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -200.6% | -423.7% | - | - | - | - | - | - | - | - |
| Return on assets | -147.6% | -300.1% | -2515.8% | -4410.2% | -3255.4% | -15464.1% | -4812.0% | -5664.8% | -9860.6% | -8275.6% |
| Current ratio | 2.55 | 1.50 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 |
| Debt to equity | - | 0.04 | - | - | - | - | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $375.7K | $169.7K | $20.0K | $60.2K | $53.5K | $54.1K | $54.4K | $61.7K | $52.4K | $65.4K | $114.0K | $16.2K |
| Selling, general and admin | -$13.78M | $6.22M | $3.63M | $4.60M | -$53.33M | $53.07M | $153.6K | $220.8K | $192.9K | $348.8K | $318.2K | $393.8K |
| Operating income | -$3.46M | -$6.40M | -$3.65M | -$4.67M | -$3.65M | -$53.13M | -$213.4K | -$290.8K | -$259.9K | -$420.9K | -$438.1K | -$417.2K |
| Interest expense | $27.7K | $38.3K | $59.0K | $305.6K | $254.5K | $104.0K | $118.9K | $86.2K | $90.0K | $133.1K | $264.5K | $178.2K |
| Pre-tax income | -$4.57M | -$6.36M | -$3.09M | -$4.84M | -$4.07M | -$54.07M | -$430.2K | -$354.3K | -$358.8K | -$527.0K | -$713.0K | -$350.9K |
| Income tax | - | - | - | - | - | - | - | - | -$237 | -$275 | -$128.6K | $0 |
| Net income | -$4.57M | -$6.36M | -$3.09M | -$4.84M | -$4.07M | -$54.07M | -$430.2K | -$354.3K | -$358.6K | -$526.7K | -$584.4K | -$350.9K |
| EPS, basic | - | -$7.00 | -$7.50 | -$9.75 | - | -$312.50 | -$805.75 | -$899.25 | - | -$13644.75 | -$38988.75 | -$1.00 |
| EPS, diluted | - | -$7.00 | -$7.50 | -$9.75 | - | -$312.50 | -$805.75 | -$899.25 | - | -$13644.75 | -$38988.75 | -$1.00 |
| Diluted shares | - | 897,099.44 | 534,414.32 | 493,261.04 | - | 173,039.76 | 533.88 | 393.96 | - | 39.76 | 15.88 | 439,587.24 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $832.0K | $443.7K | $561.2K | $602.7K | $12.1K | $50.8K | $14.6K | $9.3K | $21.1K | $6.2K | $71.7K | $6.6K |
| Current assets | $8.54M | $8.22M | $7.71M | $8.76M | $8.35M | $9.74M | $18.0K | $21.5K | $25.4K | $12.9K | $210.8K | $145.8K |
| Total assets | $12.78M | $14.33M | $15.11M | $17.98M | $19.63M | $22.53M | $78.5K | $63.6K | $72.4K | $37.3K | $241.9K | $180.4K |
| Current liabilities | $3.35M | $3.48M | $3.62M | $3.57M | $5.58M | $4.34M | $4.15M | $4.10M | $3.79M | $3.69M | $3.76M | $3.13M |
| Total debt | - | $55.0K | $55.0K | $107.0K | $537.9K | $438.6K | $409.8K | $381.8K | $399.3K | $583.0K | $687.6K | $397.4K |
| Total liabilities | $3.38M | $3.51M | $3.66M | $3.61M | $5.73M | $4.44M | $4.24M | $4.17M | $3.85M | $3.74M | $3.81M | $3.17M |
| Shareholders' equity | $9.40M | $9.83M | $10.45M | $14.36M | $13.91M | $18.09M | -$4.16M | -$4.11M | -$3.78M | -$3.70M | -$3.56M | -$2.99M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.60M | -$1.14M | -$999.1K | -$1.94M | -$92.2K | -$96.2K | $18.7K | -$235.5K | -$260.0K | -$102.8K | -$238.9K | -$333.5K |
| Capital expenditures | $21 | $154 | $2.3K | $2.5K | - | - | - | - | - | - | - | - |
| Free cash flow | -$1.60M | -$1.14M | -$1.00M | -$1.94M | - | - | - | - | - | - | - | - |
| Investing cash flow | -$21 | -$154 | -$2.3K | -$2.5K | - | - | - | - | - | - | - | - |
| Financing cash flow | $1.98M | $981.6K | $965.1K | $2.53M | $72.8K | $147.5K | $54.8K | $215.7K | $251.0K | $66.6K | $273.9K | $350.3K |
| Stock-based compensation | $1.23M | $1.77M | $2.47M | $3.02M | $3.12M | - | - | - | - | - | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.55 | 2.37 | 2.13 | 2.45 | 1.50 | 2.24 | 0.00 | 0.01 | 0.01 | 0.00 | 0.06 | 0.05 |
| Debt to equity | - | 0.01 | 0.01 | 0.01 | 0.04 | 0.02 | - | - | - | - | - | - |
Source: XBRL data Propanc Biopharma Inc. files with the SEC, latest filing dated Sep 25, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Sep 25, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PPCB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PPCB | - | - | -$18.86M | - | $1.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
PPCB FAQ
6 questionsIs PPCB profitable?
No. Propanc Biopharma Inc. reported a net loss of $18.86M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does PPCB have?
Propanc Biopharma Inc. reported $832.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PPCB free cash flow?
Propanc Biopharma Inc. generated -$5.69M of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of -$5.68M less capital expenditures.What is PPCB earnings per share?
Diluted earnings per share were -$17.62 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did PPCB last report financial results?
The latest statements here come from Propanc Biopharma Inc.'s 10-K filed on Sep 25, 2026, covering the period ended Jun 30, 2026.Where does this PPCB financial data come from?
Quantisnow builds these statements from the structured XBRL data Propanc Biopharma Inc. files with the SEC. It is provided for information only and is not investment advice.